Drugs / Ranimustine
Ranimustine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01173887 Comparator | Jul 2010 → Apr 2012 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ranimustine | “AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone)” NCT01173887 ↗ |
| Known as | Cymerin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105348 ↗ |
| Known as | NSC-270516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105348 ↗ |
| Known as | Ranimustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105348 ↗ |
| Modality | Small molecule | — CHEMBL2105348 ↗ |